Repositioning Candidate Details
| Candidate ID: | R0628 |
| Source ID: | DB04856 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Dexloxiglumide |
| Synonyms: | Dexloxiglumide |
| Molecular Formula: | C21H30Cl2N2O5 |
| SMILES: | CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1 |
| Structure: |
|
| DrugBank Description: | Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. |
| CAS Number: | 119817-90-2 |
| Molecular Weight: | 461.379 |
| DrugBank Indication: | For the treatment of Irritable Bowel Syndrome (IBS) and Gastroesophageal Reflux Disease (GERD). |
| DrugBank Pharmacology: | Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. In October 2003, following the completion of two phase III clinical studies involving dexloxiglumide in women with constipation-predominant irritable bowel syndrome (IBS), Forest Laboratories decided to discontinue development of the drug for this indication. The results of the studies showed that dexloxiglumide did not show statistically significant favorability over placebo. Rotta Research is continuing a phase III trial of a different design in Europe for the IBS indication and also for gastroesophogeal reflux disease. |
| DrugBank MoA: | CCKA antagonists target receptors in the gastrointestinal system to increase gastric emptying and intestinal motility, as well as modulate intestinal sensitivity to distension. |
| Targets: | Cholecystokinin receptor type A |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|